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Pyrimidine, being an integral part of DNA and RNA, imparts
to diverse pharmacological properties as effective bactericide
and fungicide (Williams and Cline, 1936; Reidlinger and
Dworczak, 1994; Hardtman and Otto, 1972). Certain pyrimi-dine derivatives were also known to exhibit antimalarial
(Brown and Evans, 1985), antiﬁlarial ( Brown and Rees,
1984), antioxidant (Vanessa et al., 2010; Prasenjit et al.,
2010) and anti-HIV activities (Okabe et al., 1991). Some of
the 3,4-dihydropyrimidines (DHPM) have emerged as integral
backbones of several calcium channel blockers, antihyperten-
sive agents, adrenergic and neuropeptide antagonist (Pasha
et al., 2005). Several alkaloids containing 3,4-dihydropyrimi-
dine have been isolated from marine sources and among them
the batzelladine alkaloids are found to be potent HIV-gp-120-
CD4 inhibitors (Kappe, 2000; Kappe et al., 2005; Patil et al.,
1995).
Along with the varied biological activities of pyrimidine,
other heterocycles fused with pyrimidines play an essential role
in several biological processes and have a considerable chemi-
cal and pharmacological importance. Triazole in association
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2004) and hypoglycemic action (Agarwal, 1991). [1,2,4]Tria-
zole fused pyrimidine exhibit good antimicrobial activity
(Fathy et al., 2004), antitumour activity (Swelam, 1998), anal-
gesic, anti-inﬂammatory and ulcerogenic activities (Hend
et al., 2008).
In the view of the facts mentioned above and as part of our
initial efforts to discover potentially active new agents. Hence,
we have synthesized some new dihydropyrimidinecarbonitrile
and its triazole fused derivatives. The novel derivatives were
characterized by spectral data and elemental analysis and these
compounds were used for their antioxidant and anti-inﬂamma-
tory screening. Compound 6a is one of the ﬁnal triazole deriv-
atives of pyrimidine and its intermediates 1a and 3a have
shown good antioxidant activity so we have described the elec-
tron spray ionization mass spectral fragmentation of 6a.2. Materials and methods
2.1. Materials and reagents
Unless otherwise noted, materials were obtained from com-
mercial suppliers and used without further puriﬁcation. Melt-
ing point was determined by Micro control based melting
point instrument and is uncorrected. All reactions were moni-
tored by thin-layer chromatography on 0.25 mm silica gel
(60GF-254) plates, by using ethyl acetate: butanol: chloroform
in the ratio of [1:2:1] as mobile phase and visualized with UV
light. Column chromatography was performed on silica gel
(200–300 mesh). Infra red (IR) spectra was recorded by using
KBr disk on a Thermo Nicolate IR-400 FTIR spectrophotom-
eter, 1H NMR spectra was recorded on Bruker Avance-300F
spectrometer (300 MHz) using tetramethylsilane as internal
standard (chemical shift in d ppm). Mass spectra were recorded
on a Triple Quadrupole LC–MS–MS (Sciex with ESI source)
spectrometer. The elemental analysis was carried out by using
Heraus CHN rapid analyzer. All the compounds gave C, H
and N analysis within ±1.2% of the theoretical values. Spec-
tra facilities and elemental analysis were carried out by Depart-
ment of University scientiﬁc instrument centre, Karnatak
University, Dharwad, India and Suven Life Sciences, Hydera-
bad India.
2.2. Synthesis
2.2.1. General procedure for the synthesis of 6-oxo-4-substituted
aryl-2-sulfanyl-1,6-dihydropyrimidine-5-carbonitrile (1a–c)
Mixture equimolar quantities of ethyl cyanoacetate (5.7 g,
50 mmol), thiourea (3.8 g, 50 mmol), appropriate aromatic
aldehyde (50 mmol) and potassium carbonate (6.9 g, 50 mmol)
in absolute ethanol (50 ml) was gently reﬂuxed till the comple-
tion of reaction. The reaction mixture was neutralized with
glacial acetic acid to precipitate out the product. The product
was isolated and recrystallized from ethanol as yellow crystals.
2.2.2. General procedure for the synthesis of 1-methyl-2-
(methylsulfanyl)-6-oxo-4-substituted aryl-1,6-dihydro-
pyrimidine-5-carbonitrile (2a–c)
To a solution of 6-oxo-4-substituted aryl-2-sulfanyl-1,6-dihy-
dropyrimidine-5-carbonitrile (1a–c, 20 mmol) in N,N-dimethyl
formamide (DMF, 30 ml), potassium carbonate (5.52 g,40 mmol) and methyl iodide (5.68 g, 40 mmol) were added
and stirred till the completion of reaction at room temperature.
Then the reaction mixture was diluted with cold water and
neutralized by glacial acetic acid. The product was ﬁltered
off and recrystallized from ethanol as creamy crystals.
2.2.3. General procedure for the synthesis of 2-hydrazinyl-1-
methyl-6-oxo-4-substituted aryl-1,6-dihydropyrimidine-5-
carbonitrile (3a–c)
A mixture of compound 1-methyl-2-(methylsulfanyl)-6-oxo-4-
substituted aryl-1,6-dihydropyrimidine-5-carbonitrile (2a–c,
10 mmol) and hydrazine hydrate (80%, 1.90 g, 30 mmol) in
absolute alcohol was reﬂuxed till the completion of reaction.
The reaction mixture was poured into crushed ice. Then the
product was isolated and recrystallized from ethanol/DMF
mixture as yellow crystals.
2.2.4. General procedure for the synthesis of 8-methyl-7-oxo-5-
substituted aryl-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-
carbonitrile (4a–c)
Amixture of compound 2-hydrazinyl-1-methyl-6-oxo-4-substi-
tuted aryl-1,6-dihydropyrimidine-5-carbonitrile (3a–c, 5 mmol)
in 20 ml formic acid was reﬂuxed till the completion of reaction.
The excess of formic acid was distilled. The reaction mixture
after cooling was poured into crushed ice. Then the product
was isolated and recrystallized from DMF as yellow crystals.
2.2.5. General procedure for the synthesis of 3,8-dimethyl-7-oxo-
5-substituted aryl-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrimidine-
6-carbonitrile (5a–c)
Amixture of compound 2-hydrazinyl-1-methyl-6-oxo-4-substi-
tuted aryl-1,6-dihydropyrimidine-5-carbonitrile (3a–c,
5 mmol) in 20 ml acetic anhydride was reﬂuxed till the comple-
tion of reaction. The excess of acetic anhydride was distilled.
The reaction mixture after cooling was poured into crushed
ice. Then the product was isolated and recrystallized from
DMF as yellow crystals.
2.2.6. General procedure for the synthesis of 8-methyl-7-oxo-3-
phenyl-5-substituted aryl-7,8-dihydro[1,2,4]triazolo[4,3-
a]pyrimidine-6-carbonitrile (6a–c)
Amixture of compound 2-hydrazinyl-1-methyl-6-oxo-4-substi-
tuted aryl-1,6-dihydropyrimidine-5-carbonitrile (3a–c,
5 mmol) in 20 ml benzoyl chloride was reﬂuxed till the comple-
tion of reaction. The excess of benzoyl chloride was distilled.
The reaction mixture after cooling was poured into crushed
ice. Then the product was obtained as semisolid.
The physical constants and spectral (IR, 1H NMR, mass)
characterization and elemental analysis supported the struc-
ture of various synthesized compounds (Tables 1 and 2).3. Pharmacological screening
3.1. Antioxidant screening: (in vitro)
3.1.1. Hydrogen peroxide scavenging activity
A solution of hydrogen peroxide (20 mM) was prepared in
phosphate buffer saline (pH 7.4). Various concentrations
(12.5, 25, 50, 100 lg/ml) of 1 ml of the test samples or stan-
dard, ascorbic acid (Ismaili et al., 2008; Rang et al., 2003) in
methanol were added to 2 ml of hydrogen peroxide solution
Table 1 Physical constant of synthesized compounds.
Compound Chemical name Ar Reaction time (h) Yield (%) M.P. (C) Mol. formula Rf value#
1a 6-Oxo-4-phenyl-2-sulfanyl-1,6-dihydropyrimidine-5-carbonitrile C6H5 10 53 235–238 C11H7N3OS 0.45
1b 4-(3-Methoxyphenyl)-6-oxo-2-sulfanyl-1,6-dihydropyrimidine-5-
carbonitrile
3-OCH3ÆC6H4 14 61 237–240 C12H9N3O2S 0.49
1c 6-Oxo-2-sulfanyl-4-(3,4,5-trimethoxyphenyl)-1,6-
dihydropyrimidine-5-carbonitrile
3,4,5-(OCH3)C6H2 12 63 220–222 C14H13N3O4S 0.52
2a 1-Methyl-2-(methylsulfanyl)-6-oxo-4-phenyl-1,6-
dihydropyrimidine-5-carbonitrile
C6H5 3 62 148–150 C13H11N3OS 0.56
2b 4-(3-Methoxyphenyl)-1-methyl-2-(methylsulfanyl)-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile
3-OCH3ÆC6H4 4 66 175–178 C14H13N3O2S 0.58
2c 1-Methyl-2-(methylsulfanyl)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-
dihydropyrimidine-5-carbonitrile
3,4,5-(OCH3)C6H2 4 59 210–212 C16H17N3O4S 0.6
3a 2-Hydrazinyl-1-methyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-
carbonitrile
C6H5 6 71 275–277 C12H11N5O 0.58
3b 2-Hydrazinyl-4-(3-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile
3-OCH3ÆC6H4 5 70 280–283 C13H13N5O2 0.59
3c 2-Hydrazinyl-1-methyl-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-
dihydropyrimidine-5-carbonitrile
3,4,5-(OCH3)C6H2 7 66 252–255 C15H17N5O4 0.61
4a 8-Methyl-7-oxo-5-phenyl-7,8-dihydro[1,2,4]triazolo[4,3-
a]pyrimidine-6-carbonitrile
C6H5 6 72 250–252 C13H9N5O 0.59
4b 5-(3-Methoxyphenyl)-8-methyl-7-oxo-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3-OCH3ÆC6H4 9 67 258–260 C14H11N5O2 0.57
4c 8-Methyl-7-oxo-5-(3,4,5-trimethoxyphenyl)-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3,4,5-(OCH3)C6H2 7 55 296–298 C16H15N5O4 0.62
5a 3,8-Dimethyl-7-oxo-5-phenyl-7,8-dihydro[1,2,4]triazolo[4,3-
a]pyrimidine-6-carbonitrile
C6H5 7 69 265–268 C14H11N5O 0.61
5b 5-(3-Methoxyphenyl)-3,8-dimethyl-7-oxo-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3-OCH3ÆC6H4 7 62 251–254 C15H13N5O2 0.63
5c 3,8-Dimethyl-7-oxo-5-(3,4,5-trimethoxyphenyl)-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3,4,5-(OCH3)C6H2 8 57 287–290 C17H17N5O4 0.68
6a 8-Methyl-7-oxo-3,5-diphenyl-7,8-dihydro[1,2,4]triazolo[4,3-
a]pyrimidine-6-carbonitrile
C6H5 7 61 S.S.
W C19H13N5O 0.54
6b 5-(3-Methoxyphenyl)-8-methyl-7-oxo-3-phenyl-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3-OCH3ÆC6H4 9 48 S.S.
W C20H15N5O2 0.55
6c 8-Methyl-7-oxo-3-phenyl-5-(3,4,5-trimethoxyphenyl)-7,8-
dihydro[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile
3,4,5-(OCH3)C6H2 8 54 S.S.
W C22H19N5O4 0.57
S.S.W – semisolid.
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Table 2 Spectral characterization and elemental analysis of synthesized compounds.
Compound IR (KBr) m (cm1) 1H NMR DMSO-d (ppm) Mass m/z % Calculated (found)
C H N
1a 3655 (NH), 2204 (C„N), 1633 (C‚O), 1514 (C‚N) 7.46–7.87 (m, 5H, Ar-H), 11.60 (s, 1H, NH), 1.46 (s, 1H, SH) 230.4 M+1 57.63 (57.60) 3.08 (3.05) 18.33 (18.30)
1b 3645 (NH), 2214 (C„N), 1636 (C‚O), 1581 (C‚N), 1234 (C–
O–C)
6.81–7.18 (m, 4H, Ar-H), 3.68(s, 3H, OCH3), 10.93 (S, 1H,
NH), 1.74 (s, 1H, SH)
260.3 M+1 55.59 (55.60) 3.50 (3.50) 16.21 (16.20)
1c 3631 (NH), 2203 (C„N), 1628 (C‚O), 1509 (C‚N), 1243 (C–
O–C)
7.12 (s, 2H, Ar-H), 3.53 (s, 9H, OCH3), 11.17 (s,1H,NH), 1.61
(s, 1H, SH)
320.3 M+1 52.66 (52.58) 4.10 (4.07) 13.16 (13.15)
2a 2219 (C„N), 1681 (C‚O), 1551 (C‚N), 1365 (C–N) 7.59–7.97 (m, 5H, Ar-H), 2.63 (s, 3H, S–CH3), 4.11 (s, 3H, N–
CH3)
258.3 M+1 60.68 (60.69) 4.31 (4.30) 16.33 (16.35)
2b 2217 (C„N), 1670 (C‚O), 1598 (C‚N), 1368 (C–N), 1257
(C–O–C)
6.92–7.15 (m, 4H, Ar-H), 1.96 (s, 3H, S–CH3), 2.98 (s, 3H, N–
CH3), 3.72 (s, 3H, OCH3)
288.4 M+1 58.52 (58.46) 4.56 (4.53) 14.62 (14.60)
2c 2210 (C„N), 1668 (C‚O), 1587 (C‚N), 1365 (C–N), 1242
(C–O–C)
7.08 (s, 2H, Ar-H), 2.14 (s, 3H, S–CH3), 3.21 (s, 3H, N–CH3),
4.11 (s, 9H, OCH3)
348.4 M+1 55.32 (55.34) 4.93 (4.92) 12.10 (12.12)
3a 3339 (NH–NH2), 2206 (C„N), 1695 (C‚O), 1619 (C‚N) 7.51–7.91 (m, 5H, Ar-H), 2.09 (s, 1H, NH), 2.50 (s, 2H, NH2),
3.21 (s, 3H, N–CH3)
242.4 M+1 59.74 (59.72) 4.60 (4.59) 29.03 (29.04)
3b 3261 (NH–NH2), 2218 (C„N), 1667 (C‚O), 1599 (C‚N),
1253 (C–O–C)
6.72–7.04 (m, 4H, Ar-H), 1.94 (s, 1H, NH), 2.17 (s, 2H, NH2),
2.91 (s, 3H, N–CH3), 3.88 (s, 3H, OCH3)
272.3 M+1 57.56 (57.50) 4.83 (4.80) 25.82 (25.76)
3c 3326 (NH–NH2), 2214 (C„N), 1664 (C‚O), 1595 (C‚N),
1246 (C–O–C)
6.56 (s, 2H, Ar-H), 1.83 (s, 1H, NH), 2.08 (s, 2H, NH2), 3.09 (s,
3H, N–CH3), 4.01 (s, 9H, OCH3)
333.3 M+1 54.38 (54.22) 5.17 (5.11) 21.14 (21.09)
4a 2230 (C„N), 1680 (C‚O), 1624 (C‚N), 1320 (C–N) 7.40–7.92 (m, 5H, Ar-H), 8.28 (s, 1H, CH-triazole), 2.41 (s, 3H,
N–CH3)
252.3 M+1 62.15 (62.08) 3.61 (3.57) 27.87 (21.78)
4b 2219 (C„N), 1668 (C‚O), 1599 (C‚N), 1322 (C–N),
1251(C–O–C)
7.03–7.40 (m, 4H, Ar-H), 8.32 (s, 1H, CH-triazole), 2.27 (s, 3H,
N–CH3), 3.83 (s, 3H, O–CH3).
282.4 M+1 59.78 (59.82) 3.94 (3.92) 24.90 (24.86)
4c 2217 (C„N), 1670 (C‚O), 1593 (C‚N), 1340 (C–N), 1246
(C–O–C)
6.88 (s, 2H, Ar-H), 7.94 (s, 1H, CH-triazole), 2.13 (s, 3H, N–
CH3), 3.64 (s, 9H, O–CH3).
342.4 M+1 56.30 (56.22) 4.43 (4.44) 20.52 (20.50)
5a 2229 (C„N), 1674 (C‚O), 1626 (C‚N), 1321 (C–N) 7.32–7.86 (m, 5H, Ar-H), 2.38 (s, 3H, N–CH3), 1.89 (s, 3H, C–
CH3)
266.3 M+1 63.39 (63.29) 4.18 (4.15) 26.40 (26.36)
5b 2219 (C„N), 1667 (C‚O), 1593 (C‚N), 1319 (C–N), 1251
(C–O–C)
6.94–7.47 (m, 4H, Ar-H), 2.41 (s, 3H, N–CH3), 2.76 (s, 3H, C–
CH3), 3.62 (s, 3H, O–CH3).
296.3 M+1 61.01 (60.78) 4.44 (4.39) 23.72 (23.65)
5c 2217 (C„N), 1670 (C‚O), 1594 (C‚N), 1340 (C–N), 1246
(C–O–C)
7.26 (s, 2H, Ar-H), 2.50 (s, 3H, N–CH3), 2.09 (s, 3H, C–CH3),
3.75 (s, 9H, O–CH3).
356.3 M+1 57.46 (57.38) 4.82 (4.79) 19.71 (19.66)
6a 2361 (C„N), 1668 (C‚O), 1619 (C‚N), 1318 (C–N) 7.03–8.13 (m, 10H, 2Ar-H), 2.50 (s, 3H, N–CH3) 328.3 M+1 69.71 (69.59) 4.00 (4.02) 21.39 (21.28)
6b 2372 (C„N), 1786 (C‚O), 1598 (C‚N), 1322 (C–N), 1214
(C–O–C)
6.82–7.96 (m, 9H, 2Ar-H), 2.34 (s, 3H, N–CH3), 4.22 (s, 3H,
O–CH3).
358.4 M+1 67.22 (67.18) 4.23 (4.20) 19.60 (19.57)
6c 2361 (C„N), 1687 (C‚O), 1595 (C‚N), 1324 (C–N), 1289
(C–O–C)
6.65–7.88 (m, 7H, 2Ar-H), 2.27 (s, 3H, N–CH3), 3.62 (s, 9H,
O–CH3).
418.4 M+1 63.30 (63.32) 4.59 (4.56) 16.78 (16.72)
N
o
v
el
p
y
rim
id
in
e
a
n
d
its
tria
zo
le
fu
sed
d
eriv
a
tiv
es:
S
y
n
th
esis
a
n
d
in
v
estig
a
tio
n
o
f
a
n
tio
x
id
a
n
t
9
8
9
990 C.M. Bhalgat et al.in phosphate buffer saline. The absorbance was measured at
230 nm after 10 min (Jayaprakasha et al., 2004).
3.1.2. Nitric oxide scavenging activity
The reaction mixture (6 ml) containing sodium nitroprusside
(10 mM, 4 ml), phosphate buffer saline (pH 7.4, 1 ml) and test
samples or standard, ascorbic acid solution in dimethyl sulph-
oxide (1 ml) at various concentrations (12.5, 25, 50, 100 lg/ml)
was incubated at 25 C for 150 min. After incubation, 0.5 ml of
reaction mixture containing nitrite ion was removed, 1 ml of
sulphanilic acid reagent was added to this, mixed well and al-
lowed to stand for 5 min for completion of diazotization.
Then, 1 ml of naphthyl ethylene diamine dihydrochloride
was added, mixed and allowed to stand for 30 min in diffused
light. A pink colored chromophore was formed. The absor-
bance was measured at 640 nm (Marcocci et al., 1994).
3.1.3. Lipid peroxidation inhibitory activity
Egg lecithin (3 mg/ml phosphate buffer, pH 7.4) was sonicated
in an ultrasonic sonicator for 10 min to ensure proper lipo-
some formation. Test samples (100 ll) of different concentra-
tions (12.5, 25, 50, 100 lg/ml) were added to liposome
mixture (1 ml); the control was without test sample. Lipid
peroxidation was induced by adding ferric chloride (10 ll,Ar
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Figure 1 Scheme 1. Synthetic400 mM) and L-ascorbic acid (10 ll, 200 mM). After incuba-
tion for 1 h at 37 C the reaction was stopped by adding hydro-
chloric acid (2 ml, 0.25 N) containing trichloroacetic acid
(150 mg/ml), thiobarbituric acid (3.75 mg/ml) and butylated
hydroxy anisole (0.50 mg/ml). The reaction mixture was subse-
quently boiled for 15 min, cooled, centrifuged at 1000 rpm for
15 min and the absorbance of the supernatant was measured at
532 nm and compared with that of ascorbic acid (Duh and
Yen, 1997).
For all the above antioxidant methods, experiments were
done in triplicate and average is taken, the % inhibition at dif-
ferent concentration was calculated by the following formula
% Inhibition ¼ ½1 ðVt=VcÞ  100
where, Vt = mean absorption of test compound, Vc = mean
absorption of control.
The IC-50 value was derived from the% inhibition at differ-
ent concentration.
3.2. Anti-inﬂammatory screening (in vitro)
The synthesized compounds are screened for anti-inﬂamma-
tory activity by using inhibition of albumin denaturation
technique which was studied according to Muzushima and2CH3
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Figure 2 Scheme 2. MS fragmentation diagram of 8-methyl-7-oxo-3,5-diphenyl-7,8-dihydro[1,2,4] triazolo [4,3-a]pyrimidine-6-
carbonitrile (6a).
Novel pyrimidine and its triazole fused derivatives: Synthesis and investigation of antioxidant 991Kobayashi (1968) with slight modiﬁcation. The standard
drug and test compounds were dissolved in minimum
amount of DMF and diluted with phosphate buffer saline
(pH 7.4) in such a way that concentration of DMF in all
solutions was less than 2.5%. Test solution (1 ml) containing
concentration (100 lg/ml) of drug was mixed with 1 ml of
1% albumin solution in phosphate buffer saline and incu-
bated at 27 ± 1 C in an incubator for 15 min. Denaturation
was induced by keeping the reaction mixture at 60 ± 1 C in
a water bath for 10 min. After cooling, the turbidity was
measured at 660 nm with UV–visible spectrophotometer.
Percentage of inhibition of denaturation was calculated from
control where no drug was added. Each experiment was
done in triplicate and average is taken. The diclofenac was
used as standard drug. (Robert and Morrow, 2001; Rang
et al., 2003). The percentage of inhibition was calculated
using the formula
% Inhibition of denaturation ¼ ½ðVt=VcÞ  1  100
where, Vt = mean absorption of test compound, Vc = mean
absorption of control.4. Results and discussion
4.1. Chemistry
In the present work the title compounds were synthesized by
the cyclization of three-components like arylaldehydes, thio-
urea and ethyl cyanoacetate in ethanol by using potassium
carbonate to form 6-oxo-4-substituted aryl-2-sulfanyl-1,6-
dihydropyrimidine-5-carbonitrile (1a–c), at room temperature
stirring of 1a–c with methyl iodide in DMF in presence of
potassium carbonate yields 1-methyl-2-(methylsulfanyl)-6-
oxo-4-substituted aryl-1,6-dihydropyrimidine-5-carbonitrile
(2a–c). The 2-hydrazino derivatives, 2-hydrazinyl-1-methyl-6-
oxo-4-substituted aryl-1, 6-dihydropyrimidine-5-carbonitrile
(3a–c) was obtained by heating 2a–c with hydrazine hydrate
in ethanol. Condensation of latter with formic acid afforded
the corresponding 8-methyl-7-oxo-5-substituted aryl-7, 8-dihy-
dro[1,2,4]triazolo[4,3-a] pyrimidine-6-carbonitrile (4a–c). On
the other hand, the 3-methyl derivatives 3,8-dimethyl-7-oxo-
5-substituted aryl-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrimidine-
6-carbonitrile (5a–c) and 3-phenyl derivatives, 8-methyl-7-
Table 4 Anti-inﬂammatory activity of the compounds and
standard diclofenac sodium.
Compound Mean
absorbance ± S.D.a
Inhibition of
denaturation (%)
Control 0.0468 ± 0.0003
Standard 0.0861 ± 0.0001 83.97
1a 0.0559 ± 0.0008 19.44
1b 0.0499 ± 0.0020 66.24
1c 0.0498 ± 0.0010 64.10
2a 0.0529 ± 0.0025 13.03
2b 0.0794 ± 0.0004 69.66
2c 0.0554 ± 0.0026 18.38
3a 0.0584 ± 0.0046 24.79
3b 0.0824 ± 0.0007 76.07
3c 0.0615 ± 0.0016 31.41
4a 0.0556 ± 0.0014 18.80
4b 0.0671 ± 0.0019 43.38
4c 0.0533 ± 0.0046 13.89
5a 0.0487 ± 0.0005 04.06
5b 0.0619 ± 0.0006 32.27
5c 0.0709 ± 0.0009 51.50
6a 0.0567 ± 0.0020 21.15
6b 0.0579 ± 0.0018 23.72
6c 0.0507 ± 0.0024 08.34
a Average of three determination.
992 C.M. Bhalgat et al.oxo-3-phenyl-5-substituted aryl-7,8-dihydro[1,2,4]triazolo[4,3-
a]pyrimidine-6-carbonitrile (6a–c) were prepared by the
condensation with acetic anhydride and benzoyl chloride,
respectively (Fig. 1).
All the pyrimidines and their [1,2,4]triazole fused pyrimi-
dine derivatives were synthesized and conﬁrmed by physical
data, IR, 1H NMR, mass spectra and elemental analysis. All
the compounds have shown C„N peak in 2220–2200 cm1,
C‚O peak in 1700–1625 cm1, C‚C peak in 1555–1470
cm1. While the methoxy and trimethoxy derivatives have
showed the C–O–C peak in 1255–1230 cm1. The 1a–c com-
pounds showed peak in 3631–3653 cm1 for the N–H stretch
in IR and 10.93–11.17 (s, 1H, NH‚SH) peak in 1H NMR,
which is absent in 2a–c compounds. While 2a–c has shown
2.98–4.11 peak for N–CH3 and 1.96–2.63 peak for S–CH3 in
1H NMR. The 3a–c compounds showed the peak in 3340–
3280 cm1 for the NH–NH2 in IR and 1.83–2.09 for NH
and 2.08–2.50 for NH2. The fused triazoles (4a–c, 5a–c and
6a–c) were not showing the N–H stretch in IR and NH,
NH2 peak in
1H NMR. The mass spectrum of 6a showed an
intense molecular ion peak at m/z 328 (M+1) corresponding
to molecular formula C19H13N5O. This was found to be the
base peak. M+1 ion of 6c underwent fragmentation to pro-
duce a peak at m/z 250 by losing C6H5 (m/z 77). Simulta-
neously a peak at m/z 210 was observed by losing
C6H5C‚N–N (m/z 117). C6H5C‚N–N ion underwent further
fragmentation to give peak at m/z 89 for C6H5C ion. The ion
at m/z 89 underwent loss C to give peaks at m/z 77 (C6H5).
Fragmentation pattern of 6a has been shown in Fig. 2.
4.2. Pharmacological screening
4.2.1. Antioxidant activity
All the synthesized compounds were screened for in vitro anti-
oxidant activity by various methods as scavenging of hydrogen
peroxide, scavenging of nitric oxide radical, lipid peroxidationTable 3 Antioxidant activity (IC-50 values) of synthesized compou
Compound IC-50 (Mean ± S.D.)a (lg/ml)
Scavenging of nitric oxide radical Scavenging
Standard 56 ± 0.087 38 ± 0.121
1a 67 ± 0.121 43 ± 0.024
1b 78 ± 0.318 52 ± 0.318
1c 51 ± 0.058 41 ± 0.087
2a 108 ± 0.78 63 ± 0.279
2b 87 ± 0.082 59 ± 0.333
2c 85 ± 0.162 55 ± 0.453
3a 74 ± 0.081 41 ± 0.066
3b 47 ± 0.052 52 ± 0.279
3c 53 ± 0.066 45 ± 0.087
4a 97 ± 0.453 57 ± 0.318
4b 88 ± 0.183 68 ± 0.121
4c 91 ± 0.318 83 ± 0.318
5a 99 ± 0.453 82 ± 0.066
5b 85 ± 0.045 84 ± 0.162
5c 92 ± 0.024 89 ± 0.087
6a 112 ± 0.333 103 ± 0.02
6b 104 ± 0.279 92 ± 0.121
6c 110 ± 0.318 85 ± 0.183
a Average of three determination.inhibitory activity. In vitro antioxidant activity of synthesized
compound is summarized in Table 3.
The investigation of antioxidant screening revealed that
some of the tested compounds showed moderate to good anti-
oxidant activity. Particularly, compounds3a, 3c, 1a, 1c, 3b and
3c have shown more promising antioxidant activity as com-
pare to standard, ascorbic acid, while other derivatives are
moderately active. 1c has shown good antioxidant activity as
compare to standard by scavenging of nitric oxide radicalnds and standard ascorbic acid.
of hydrogen peroxide Lipid peroxidation inhibitory activity
26 ± 0.333
37 ± 0.183
42 ± 0.453
40 ± 0.121
59 ± 0.066
70 ± 0.024
64 ± 0.121
34 ± 0.162
43 ± 0.333
48 ± 0.183
56 ± 0.066
60 ± 0.318
65 ± 0.045
58 ± 0.087
61 ± 0.162
64 ± 0.453
4 71 ± 0.279
73 ± 0.318
63 ± 0.087
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showed most potent antioxidant activity by scavenging of ni-
tric oxide radical method.
4.2.2. Anti-inﬂammatory activity
Synthesized compounds were also tested for anti-inﬂammatory
activity. Compared to the standard Diclofenac sodium, they
have shown acceptable anti-inﬂammatory activity. In vitro
anti-inﬂammatory activity of synthesized compounds is sum-
marized in Table 4 and Fig. 6. Among the tested compounds,
3b, 2b, 1b and 1c showed better anti-inﬂammatory activity.
Amongst all 3b found with most potent activity.5. Conclusion
The synthesized compounds were tested for antioxidant and
anti-inﬂammatory activity. In antioxidant activity 1a–c
and 3a–c derivatives have shown more promising results. This
may be due to the available NH and SH group present in 1a–c
and NH–NH2 present in 3a–c. Few synthesized compounds
have shown good anti-inﬂammatory action, amongst 3b has
shown excellent activity. Observed good anti-inﬂammatory
activity may be due to 3-OCH3 group present in structure
and may be reduced in trimethoxy compound due to its
OCH3 group at para position. This observation may promote
a further development of this group of pyrimidines may lead to
compounds with better pharmacological proﬁle than standard
antioxidant and anti-inﬂammatory drugs.Acknowledgments
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